Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06208332 · ClinicalTrials.gov registry record · Phase 2
The "What Is Important to Us" Communication Intervention Pilot Clinical Trial
A Phase 2 study of Critical Illness and Neurologic Disorder, sponsored by Seattle Children's Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT06208332: Recruiting Phase 2 study of Critical Illness and Neurologic Disorder, sponsored by Seattle Children's Hospital.
NCT06208332 is a Phase 2 study of Critical Illness and Neurologic Disorder that is actively recruiting participants, run by Seattle Children's Hospital. The registered enrollment target is 160 participants, below the 3,137-participant average among 91 other Critical Illness trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06208332, a Phase 2 study of Critical Illness and Neurologic Disorder, is actively recruiting participants, sponsored by Seattle Children's Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to conduct a pilot randomized controlled trial (RCT) of a photo-narrative communication intervention developed by our study team with patients/parents of children with severe neurological impairment (SNI) and their pediatric intensive care unit (PICU) clinicians to assess feasibility, acceptability, and early efficacy.
Primary Outcome
Feasibility will be set at a benchmark of 70% and assessed by calculating: 1) the percent enrolled (total enrolled/total approached), plus a 95% confidence interval; and 2) the percent completion (parents completing intervention/total in intervention arm), plus a 95% confidence interval.
Conditions Studied
Interventions
- BEHAVIORAL "What Is Important to Us" Communication Intervention
Study Locations (1)
Washington
- Seattle Children's Hospital - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-02-10 |
| Est. Completion | 2027-05-15 |
| Phase | Phase 2 |
What NCT06208332 shows while recruiting
NCT06208332 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 3,137-participant average among 91 other Critical Illness trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Critical Illness appearing as the primary indexed condition, and to 1 intervention - of which "What Is Important to Us" Communication Intervention is the first listed.
NCT06208332 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT06208332 about?
NCT06208332 is a clinical study titled "The "What Is Important to Us" Communication Intervention Pilot Clinical Trial". The objective of this study is to conduct a pilot randomized controlled trial (RCT) of a photo-narrative communication intervention developed by our study team with patients/parents of children with severe neurological impairment (SNI) and their pediatric intensive care unit (PICU) clinicians to ass...
What is the current status of trial NCT06208332?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2025-02-10. Estimated completion is 2027-05-15.
What conditions does trial NCT06208332 study?
This clinical trial studies the following conditions: Critical Illness, Neurologic Disorder.
What interventions are being tested in trial NCT06208332?
The interventions under investigation include: "What Is Important to Us" Communication Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT06208332?
This trial is sponsored by Seattle Children's Hospital, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06208332 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Critical Illness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06208332's enrollment target sits among peer trials
160 53rd of 91 higher than 38 of 91 other Critical Illness trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Critical Illness trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Azithromycin for Critical Asthma - Pediatrics
RECRUITING · Phase 2
-
Practical Anemia Bundle for SusTained Blood Recovery
COMPLETED · Phase 2
-
Hypovitaminosis D in Neurocritical Patients
COMPLETED · Phase 2
-
Inulin for Infections in the Intensive Care Unit
COMPLETED · Phase 2
-
Preoperative Fasting vs. Not Fasting in Critically Ill Patients
RECRUITING · NA
-
Assessment of Stroke Volume in Shock Using Echocardiography Versus Bioreactive Impedance
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI